As a co-sponsor of this conference, GENTIS’s participation further demonstrates its strong commitment to promoting the application of genetic medicine in reproductive healthcare. Beyond providing advanced technological solutions, GENTIS contributed to the professional program with up-to-date content aimed at practical value for doctors and specialists.
One of the key highlights introduced by GENTIS at the conference was two modern genetic testing solutions widely applied in Vietnam, recently certified by the College of American Pathologists (CAP)—one of the top international standards for medical laboratories. Among them, the NIPT test (Non-Invasive Prenatal Testing) is increasingly becoming the standard in modern pregnancy management. With the ability to detect genetic abnormalities as early as the 9th week of pregnancy using only maternal blood samples, NIPT minimizes risks associated with invasive procedures like amniocentesis, while providing accurate information for doctors and expectant mothers to make informed medical decisions. Discussions at the conference clearly emphasized the importance of broad NIPT implementation, especially given the still-high rates of late detection of congenital abnormalities in many localities.
Additionally, GENTIS highlighted the role of PGT (Preimplantation Genetic Testing) in the field of assisted reproduction. Embryo screening before transfer—not only improving IVF success rates but also reducing the risk of passing genetic disorders to the next generation. With the rising rate of infertility and increasing demand for healthy childbirth, applying PGT has become an essential part of IVF protocols at many leading fertility centers. GENTIS currently offers PGT-A, PGT-M, and PGT-SR tests, expanding screening capabilities from chromosomal abnormalities to complex single-gene disorders.
Notably, at this conference, GENTIS proudly sponsored a scientific report titled “Gene Therapy in Fetuses: From Potential to Clinical Practice,” presented by Dr. Nguyen Van Thong—Head of Medical Genetics Department, Hung Vuong Hospital. The report attracted significant attention from the professional community as it discussed the emerging and promising field of gene therapy in fetal medicine. Developing gene therapies administered before birth, if systematically advanced, could fundamentally change the approach to treating congenital genetic diseases in Vietnam in the near future. This aligns with GENTIS’s long-term vision—not only providing genetic testing services but also accompanying the medical community in research, application, and technology transfer of advanced medical innovations.
HSMFM 2025 also served as a forum for experts to deeply discuss the standardization of fetal screening, diagnosis, and intervention processes, sharing experiences in managing high-risk pregnancies, and enhancing genetic counseling capacity. Case discussion sessions provided fresh insights, highlighting the urgent need for continuous knowledge updates and applying scientific technology to improve treatment quality.
By partnering with HSMFM 2025, GENTIS not only demonstrated its role as a reputable provider of genetic medicine services but also as a crucial link in Vietnam’s healthcare innovation ecosystem. This event marked another important milestone in GENTIS’s ongoing journey to contribute to building a preventive, precise, and personalized healthcare system, aiming to improve quality of life from the earliest stage—right from the womb.
